Orion Corporation has evaluated strategic alternatives of its Global Operations and has decided to investigate the possible sale of its pharmaceutical manufacturing plant in Kuopio or other transaction that would result in transfer of the plant outside the Orion Group. The new owner of the plant would continue the manufacture of products in Kuopio as a contract manufacturer. The products would continue to be a part of Orion’s product portfolio.
A possible outcome of the investigation may also be that Orion will remain as the owner of the plant in question. Orion’s manufacturing plant in Kuopio specialises in liquids and self-care products. Among the most widely known of these are nasal sprays, cough medicines, and ear drops.
The Kuopio plant has about 50 employees in the global operations. Orion’s Global Operations and Quality management consists of about 1,800 employees in total.
Contact person:
Terhi Ormio
Vice President, Communications, Orion Corporation
Tel. +358 50 966 4646
terhi.ormio@orion.fi
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi/en
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million, and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.